Ruxolitinib

JAK Janus Kinase

32450201 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
32470486 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
32405693 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
32518419 2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
32528040 2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
32585295 2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
32555296 2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
32593183 2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
32581810 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
32629531 2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
32636055 2020. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
32727701 ?. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
32814839 2020. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
32818929 2020. Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.
32850921 2020. Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol.
32879427 2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
32902339 2020. Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant).
32980157 2020. Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.
33131470 2020. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
33173161 2020. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
33194871 2020. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.
33195828 2020. Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity.
33242734 2020. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.